Ipilimumab in Combination with Nivolumab Is Active in Recurrent and/or Metastatic Nasopharyngeal Carcinoma
Findings from a first phase II study of this combination in nasopharyngeal carcinoma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Progression-Free Survival Improvements Favour Pembolizumab Plus Chemotherapy Over Chemotherapy in Patients with Advanced TNBC Enrolled in Asia
Patients enrolled from Asia demonstrated consistent findings with those in the overall population of the KEYNOTE-355 study
Efficacy Is Mantained When Niraparib Dose Is Tailored to Patient Characteristics in Platinum-Sensitive Recurrent Ovarian Cancer
Chinese patients receiving niraparib, a potent inhibitor of PARP 1/2, benefited from an individualised starting dose
Neoadjuvant Pembolizumab Improves Pathological Complete Response at Surgery in Asian Patients with Early TNBC
Subgroup of Asian patients with triple negative breast cancer demonstrates similar reponse as observed in patients overall in the KEYNOTE-522 study
Olaparib Maintenance Reduces the Risk of Recurrence in Newly Diagnosed Patients with Advanced Ovarian Cancer Harbouring a BRCA Mutation
The benefits in patients with advanced ovarian cancer and a BRCA mutation lasted well-beyond the two-year olaparib maintenance treatment
Promising Benefit Seen with Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Findings of the Chinese phase II study with novel, orally administered tyrosine kinase inhibitor
Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with Advanced Tumours and Mismatch-Repair Deficiency
Envafolimab provided responses across various tumour types
The ELSA-seq Assay Provides Early Detection and Localisation Information in Multiple Cancers
The non-invasive ELSA-seq blood-based methylation sequencing assay demonstrated sensitivity and specificity
Futabatinib for Patients with Intrahepatic Cholangiocarcinoma and FGFR2 Fusions or Rearrangements
Intrahepatic cholangiocarcinoma has a higher incidence in Asian than in Western countries and carries a poor prognosis
Risk Factors for Recurrence Among Patients From Asia with Early Breast Cancer
Characteristics of patients from Asia enrolled in monarchE study
EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab)
Subcutaneous, fixed-dose combination of pertuzumab and trastuzumab is intended for the treatment of early and metastatic breast cancer
Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab Plus Ipilimumab as First-Line Treatment in Poor- and/or Intermediate-Risk Advanced RCC
Scientific assessment report following the application for a marketing authorisation published in “ESMO Open – Cancer Horizons”